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The heavy chain of coagulation factor VII contains a serine &erase entity. A partial cleavage in the heavy chain occurs during purification and 
activation of the single-chain zymogen. presumably as a result of autolysis. Neutrophil cathepsin G initially generates a Gla-domainless FVIIa 
without coagulant activity. However, on extended exposure cleavage also occurs in the heavy chain, resulting in a complete loss of enzyme activity. 
Four cleavage sites on the heavy chain. two susceptible to trypsin-like autolysis and two susceptible to chymot~psin-like cathepsin G-mediated 
catalysis have been identified. The hydrolysis of peptide bonds in the heavy chain might contribute to regulation of the coagulation process in vivo. 
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1. I~RO~UCTION 
Coagulation factor VII consists of 406 amino acids 
with a serine esterase domain in the C-terminal part of 
the molecule [l]. The trypsin-like serine esterase be- 
comes active towards its substrates FX and FIX after 
cleavage of a single peptide bond between Arg-I 52 and 
Ile-153, leaving two chains, covalently linked by one 
disulfide bridge. Several coagulation enzymes are capa- 
ble of activating FVII, a process which is greatly en- 
hanced by the binding to tissue factor and negatively 
charged phospholipids [2,3]. Single-chain FVII is con- 
verted to the two-chain form (FVIIa), when bound in 
sufficient density to charged surfaces [4,5], and evidence 
for autoactivation has been presented [6]. However, 
after activation, a minor degree of cleavage in the heavy 
chain of the purified plasma and recombinant FVIIa 
has been found f7]. Heavy chain cleavage of FVIIa was 
also observed after incubation with cathepsin G from 
human neutrophilic granulocytes 181. We have identified 
four sites on the heavy chain, which are susceptible to 
proteolytic attack under non-denaturing conditions, 
and which might possibly be exposed to enzymes pres- 
ent during hemostasis and i~fla~ation. Cleavage at 
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these sites might be a first step in the in vivo degradation 
of FVIIa. 
2. EXPERIMENTAL 
Recombinant FVIIa [7], 1 mg!ml was dialysed against 10 mM Tris- 
HCl, pH 8.6, containing 75 mM NaCl and 5 mM CaCl?. Calcium ions 
were complexed with EDTA, added in an excess of 5 mM, before the 
incubation with cathepsin G at 37°C. The final pH of the incubation 
mixture was 7.6. Cathepsin G, purified from human neutrophiles 
according to the method of Baugh and Travis [9] was a gift from Drs. 
H.J. Flodgaard and 0. Nordfang (Novo Nordisk, Copenhagen). 
Specific clotting activity was determined in a one-stage FVII clot- 
ting assay, based on FVII immunodepleted human plasma and rabbit 
thromboplastm. 
The substrate for amidolytic activity was S-2288 Ile-Pro-Arg-p- 
nitroanilide (KABI Vitrum, Sweden). The rFVIIa was diluted to 0.15 
PM in 0.1 M Tris-HCl, 0.1 M NaCl, 5 mM CaCl,, pH 8.3, containing 
0.1% PEG-6000, and substrate was added to a final concentration of 
1 mM. The absorption at 405 nm was read after 30 min Incubation 
at 37°C. 
Reduction with DTT was performed overnight at room temperature 
in 0.3 M Tris-HCl, pH 8.1 containing 6 M guanidine hydrochloride. 
Iodoacetamide was added for carboxymethylation of free sulfhydryl 
groups. Excess reagents were removed by dialyses in tubing with a 
molecular cut-off of 3,500. 
RP-HPLC, SDS-PAGE and amino acid sequence analysis were 
performed as previously described [7,8,10]. 
ES-MS analysis was performed using an API III LCIMSIMS system 
(Sciex, Thomhill. Ontario, Canada). The tnple quadrupole instrument 
has a mass-to-charge (m/r) range of 2,400 and is fitted with a pneumat- 
ically assisted electrospray (also referred to as ion-spray) interface 
[11,12]. Sample introduction was done by a syringe infusion pump 
(Sage instruments, Cambridge, MA) through a fused capillary (7.5 ,um 
i.d.) with a liquid Row-rate set at 0.5--l @/min. The instrument m/z 
scale was calibrated with the singly charged ammomum adduct ions 
of poly(propylene glycols) under unit resolution. 
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3. RESULTS 1234 5 6 7 8 9 10 II 12 
3.1. Heavy-chain cleavage, present after purification and 
activation 
3.1 .I. SDS-PAGE, RP-HPLC, amino acid sequence. 
Recombinant FVII is activated to rFVIIa during pu- 
rification [5,7]. SDS-PAGE of the reduced molecule 
shows the H- and L-chain, and in addition traces of four 
bands in the region 16-19 kDa (Fig. 1, lane 2). RP- 
HPLC of the purified rFVIIa revealed two minor peaks 
eluted in front of the main protein [7]. The SDS-PAGE 
analysis of the first of these minor peaks showed a 
two-chain structure of 36 kDa, consisting of a 16 kDa 
band, covalently linked to the L-chain, and N-terminal 
amino acid sequence analysis confirmed the sequences 
for the intact L- and H-chain, starting at Ala-l and 
Ile-153. respectively (data not shown). The second 
minor peak contained a single peptide chain of 17 kDa, 
with an N-terminal sequence starting at Gly-291 (Table 
I, sequence A). 
KD 
94 
68 
43 
30 
20 
14 
Time (min) 020120 0 5 10 20 60 120 
C&12 (5 mM) + + + 0 0 0 0 0 0 
Clot activity (96) 100 35 9 100 0 0 0 0 0 
Amidolytic act. (W) 100 ND ND 100 ND 92 96 60 21 
The remaining two bands of 19 and 17 kDa (Fig. 1, 
lane 2) were present in the main protein peak from 
RP-HPLC. When the predicted residues for the L- and 
H-chain were disregarded, N-terminal amino acid se- 
quencing revealed a sequence, starting at Lys-3 16, and 
corresponding to a cleavage in the third loop of the 
heavy chain (Table I, sequence B). 
Fig. 1. SDS-PAGE and activity of cathepsin G degraded rFVIIa. 
rFVIIa (1 mg/ml) was incubated with cathepsin G (l/SO w/w) at 37°C 
in the presence and absence of calcium ions. At the indicated intervals, 
aliquotes were either diluted into 1% SDS, 1% DTT and boiled for 
SDS-PAGE, or diluted into Ca” containing buffer on ice for clotting 
analysis or diluted into substrate containing buffer for measuring 
amidolytic activity. Molecular weight markers were applied in lanes 
1 and 12. ND, not determined. 
The observed SDS-PAGE pattern is consistent with 
a cleavage after Arg-290 (y cleavage site in Fig. 4), 
resulting in an L-linked fragment 153-290 (lowest band 
of 16 kDa) and a non-covalent fragment 291406 con- 
taining the N-linked carbohydrate at Asn-322 (band at 
17 kDa), and a cleavage after Arg-315 @ cleavage site 
in Fig. 4), resulting in three covalently linked chains, the 
L chain, the fragment 153-315 (upper band of 19 kDa) 
and the fragment 31f%406 carrying the N-glycan (band 
at 17 kDa). Since the heavy-chain cleaved forms could 
not be isolated under non-denaturing conditions, the 
clotting activity of the individual forms could not be 
analysed. 
3.2. Heavy-chain cleavage by cathepsin G mediated ca- 
talysis 
3.2.1. SDS-PAGE and enzymatic activity. In the ab- 
sence of calcium ions, and a ratio of cathepsin G to 
rFVIIa of 1:500 w/w, rFVIIa is completely converted to 
a Gla-domainless form within five minutes. At a higher 
enzyme/substrate ratio (1:50 w/w), a des (144) rFVIIa 
was identified as the main product after 20 min of incu- 
bation [8]. Heavy-chain cleavage is detectable by SDS- 
PAGE after 60 min of incubation, generating three 
chains (Fig. 1, lane lo), and the H-chain is completely 
degraded after 120 min of incubation, giving rise to 
-H 
-L 
GD-L 
Table I 
Amino acid sequence analysis of rFVIIa fractions from RP-HPLC 
A. Minor peak 
Cycle no. 1 2 3 4 5 6 7 8 9 IO 11 12 
PTH-aa Gly Ala Thr Ala Leu Glu Leu Met Val Leu Asn Val 
Yield in pmol 169 164 46 140 124 117 125 117 124 87 128 121 
B. Mam peak* 
Cycle no. 1 2 3 4 5 6 7 8 9 IO 11 12 
PTH-aa LYS Val Gly Asp Ser Pro Asn Ile Thr Glu Tyr Met 
Yield in pmol 92 168 77 136 203 149 160 177 84 
*In addition to the NH,-terminal sequences for the L-chain (Ala-Asn-Ala-Phe-Leu-) and the H-chain (Ile-Val-Gly-Gly-Lys-), the sequence shown 
was recovered. In cycles 2 and 3 the heavy chain and the derivative release the same amino acids. The Asn in cycle 7 is glycosylated. 
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bands of molecular weight close to and below 15 kDa 
(Fig. 1, lane 11). In the presence of calcium ions, cleav- 
age of both the L- and H-chain is delayed (Fig. 1, lane 
4). 
While the tissue factor-dependent clotting activity is 
reduced in parallel with the formation of Gla-domain- 
less rFVIIa, the enzymatic activity towards a low-mo- 
lecular substrate is lost with the cleavage of the H-chain, 
and 5% of the amidolytic activity of the control remains 
after 3 h of incubation with cathepsin G. 
From Fig. 1 is seen that the H-chain degradation 
fragments (16-19 kDa), present before addition of 
cathepsin G changes position in the SDS-PAGE gel, 
indicating at least two cleavage sites, one in between 
residues 153 and 290 and another in between residues 
316 and 406. 
3.2.2. RP-HPLC and N-terminal sequence analysis. 
The pattern on RP-HPLC after extended cathepsin G 
exposure (1:50, 120 min), is shown in Fig. 2. As the 
GD-rFVIIa peak (Rt 27 min) diminish, two main peaks 
with Rt 24 and 26 min, appear. Analysed by SDS- 
PAGE, the former peak contained the GD-L chain with 
the 15 kDa band covalently linked, and N-terminal 
amino acid sequence analysis confirmed the Ser-45 se- 
quence from the GD-L-chain and the Ile-153 sequence 
from the H-chain. The fragment eluted at 26 min had 
an N-terminal sequence starting at Ser-333 (Table II), 
confirming the cleavage in between residues 3 16 and 
406, predicted from SDS-PAGE (S cleavage site in Fig. 
4). 
3.2.3. ES-MS. The fragments, isolated by RP-HPLC 
were applied to ES-MS. The mass obtained for the frag- 
ment starting at Ser-333 was 8,152 (Fig. 3a), confirming 
an intact C terminus of the rFVIIa. The theoretical 
value, calculated from amino acid sequence of 333406 
is 8,153. As the L-chain contains 0- and N-linked car- 
bohydrate, the mass for the L-linked heavy chain frag- 
ment could not be calculated from the amino acid con- 
tent. In order to characterize this fragment, the cathep- 
sin G-treated rFVIIa was reduced and alkylated before 
fractionation on RP-HPLC (data not shown). Analysis 
by ES-MS gave beside the mass for the alkylated 333- 
406 fragment of 8,268 (the theoretical mass is 8,267) a 
fraction containing the mass of 14,259 (Fig. 3b). The 
Absorbance at 214 nm 
0 10 20 
Time (min) 
/I JL _ 
30 
Fig. 2. RP-HPLC of cathepsin G degraded rFVIIa. 0.5 mg of rFVIIa 
incubated 120 min at 37°C with cathepsin G (l/50 w/w) were applied. 
Fractions, absorbing at 214 nm were collected and concentrated by 
evaporation. 
calculated value for the alkylated fragment 153-278 is 
14,260. The cleavage between 153 and 290, predicted 
from the SDS-PAGE pattern, therefore occurs after 
Phe-278 (E cleavage site in Fig. 4). 
A heavy chain fragment, corresponding to 279-332, 
and containing the N-linked carbohydrate was not re- 
covered. It might have been further degraded or lost 
during RP-HPLC. 
4. DISCUSSION 
A single peptide bond, between Arg- 152 and Ile- 153, 
is cleaved during the activation of FVII, converting the 
single-chain proenzyme to the coagulant active two- 
chain FVIIa. In the presence of calcium and phospho- 
lipid, a second slower cleavage followed the activation 
of human plasma FVII by human FXa, or by FIXa and 
FIIa at higher concentrations, producing a third band 
of lower molecular weight than the light chain, which 
could be seen as a triplet on stained SDS-PAGE [13]. 
The third band appeared after the activation of FVII 
was completed, and concomitant with the increasing 
amount of this third chain, the clotting activity de- 
Table II 
Amino acid sequence analvsis of catheusin G degraded rFVIIa 
Cycle no. 1 2 3 4 5 6 7 8 9 10 11 12 
PTH-aa 
Yield in pmol 
Ser Asp Gly 
269 397 380 
* * * 
Ser 
161 
LYS 
342 
* 
Asp Ser 
377 126 
CYS LYS Gly Asp Ser 
_ 348 380 196 76 
* * 
*The same amino acids are released from the (45-l 52) L-chain and/or the H-chain. The amount of Gla-domainless rFVIIa present in the RP-HPLC 
fraction (RT 26 min) corresponded to 10%. PTH-Cys is not determined. 
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Fig. 3. ES-MS of cathepsin G degraded rFVIIa derivatives. (a) The 
spectrum of RP-HPLC fraction (RT 26 mm) from Fig. 2. (b) The 
spectrum shows a fraction from RP-HPLC of reduced and alkylated 
cathepsin G degraded rFVIIa. 
creased. When the experiment was repeated in plasma, 
the third chain was not formed [13]. 
Also bovine FVII was reported to be cleaved slowly 
in the heavy chain after the rapid activation by FXa, to 
give a proteolytic inactive three chain structure [4]. The 
inactivating cleavage occurred between an Arg-Gly 
bond [14], which was later identified as the bond be- 
tween Arg-290 and Gly-291 [ 151. 
We have found that cleavage occurs not only in the 
same position, after Arg-290 in the human rFVIIa mol- 
ecule, but also after Arg-3 15. The heavy chain cleavages 
could be demonstrated after the activation, which oc- 
curred during purification 171. Several coagulation en- 
zymes have been reported to activate FVII, in addition 
to FVIIa itself, and although the possibility of trace 
amount of a contaminating enzyme cannot be excluded, 
our preliminary data indicate that the heavy-chain 
& 
2781 
cleavage at the two tryptic sites, exposed after the con- 
version of single chain to double chain can be mediated 
by FVIIa itself. 
Autolysis of coagulation enzymes is known from 
human FIIa, where the a-form is converted to /3 and y 
forms by cleavage of the B-chain. The latter cleavage 
occurs in a region [16], equivalent to the 290-291 cleav- 
age in the FVIIa molecules. When compared to other 
vitamin K-dependent coagulation enzymes, this region 
has a minimal conservation of amino acid sequence; it 
is located on the surface of the enzymes near the active 
site and it is believed to be essential for defining the 
substrate specificity [17,18]. The conservation of the se- 
quence in this region of human (L-D-R-G-A-T-A) and 
bovine FVII (L-E-R-G-V-T-A) supports this hypothe- 
sis. 
The cleavage after 315 occurs in a region, which on 
the crystal structure of trypsin is opposing the 290 re- 
gion, and which is unique to FVII in comparison with 
other vitamin K dependent enzymes, due to the inser- 
tion, 311-315. While the human FVII contains two ad- 
jacent basic residues (L-Q-Q-S-R-K-V-G-D-S-P), the 
bovine FVII has a Gln residue in between the two basic 
residues (L-Q-Q-S-R-Q-R-P-G-G-P), and cleavage in 
the bovine FVII in this position was not reported [4]. In 
that sense, the 315 cleavage might be unique for the 
human FVIIa, in the same way as the autolysis of FIIa, 
producing the y-form is obtained for human FIIa, but 
not for bovine FIIa. 
The conformational change induced by surface bind- 
ing, rendering the FVIl susceptible to autoactivation, 
might expose areas on the molecule, which are essential 
for the substrate specificity, but at the same time suscep- 
tible for proteolytic attack. The in vitro situation with 
concentrated pure enzyme, bound to charged surface 
matrices, might be parallelled to a certain degree in 
vivo, by the tissue factor binding of FVII on the cell 
surface, creating a localized high concentration of 
bound enzyme. Regulation by inhibitors TFPI and 
AT111 is probably predominant immediately after the 
initiation of the coagulation, before a possible slower 
inactivation by proteolysis plays a significant role. 
Cathepsin G has been shown to remove the Gla- 
domain of vitamin K-dependent coagulation factors at 
a position, corresponding to Phe-40-Trpdl in plasma 
FVII [19]. Using a higher ratio of enzyme to substrate, 
we found cleavage at Tyr-44Ser-45 in the L-chain [8], 
290; 
Val-Arg-Phe-Ser-Leu-Val-Ser-Gly-Trp-Gly-Gln-Leu-Leu-AspArg-Gly-AlAla 
P 
3151 332; 
Gln-Ser-Arg-Lys-Val-Gly-Asp-Ser-Pro-Asn-Ile-~-Glu-Tyr-Met-~e-Cys-~a-Gly-T~-Ser-As~Gly-Ser 
Fig. 4. Cleavage sites in the heavy chain of rFVIIa, B and y exposed by activation. and 6 and E susceptible to cathepsin G catalysis. 
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and on prolonged exposure, H-chain cleavage. Two 
cleavage sites on the H-chain have been identified, one, 
Tyr-332-Ser-333, occurring at a sequence identical to 
the L-chain cleavage at Tyr-44 (Y-S-D-G), was deter- 
mined by N-terminal sequence analysis, while a second 
site, Phe-278~Ser-279 could be deduced from analysis of 
recovered fragments by ES-MS. 
The accuracy of mass measurements on a triple quad- 
rupole instrument is generally better than 0.02%, al- 
though low-intensity spectra may result in poorer mass 
precision. The spectra, shown in Fig. 3a and b, both 
display relatively broad peaks, due to the formation of 
a sodium-adduct ion. However, the adduct-ions are 
clearly resolved from the protonated molecular ion, on 
which the mass determination is based, and they do not 
interfere with the precision of the molecular weight de- 
termination. ES-MS is a very powerful tool for struc- 
tural characterization, and the analysis reported here 
confirmed an intact C-terminus of the recombinant 
FVIIa molecule. 
The 279-332 fragment was not recovered and might 
have been further degraded. 
In vitro, calcium ions were found to have a protective 
role in the L-chain and H-chain cleavages, while heparin 
potentiated the heavy chain cleavage by cathepsin G 
(data not shown). Other coagulation enzyme degrada- 
tion patterns are influenced by heparin, which might act 
as a template for the catalysis mechanism [20] and cell 
surface proteoglycans, presumably have a modulating 
effect, in directing the proteolysis rate, in vivo. Cathep- 
sin G is released from stimulated neutrophils and might 
be a possible link between the hemostasis and inflam- 
mation processes. 
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